Skip to content
OpenCapital
Get started

United Therapeutics UTHR Remodulin — Gross Profit

Other product segments

Tyvaso DPI
$247.1M-2.9%
Orenitram
$128.2M+14.1%
Nebulized Tyvaso
$118.6M-23.6%
Unituxin
$48.6M-8.3%
Adcirca
$1.9M-44.1%

Similar metrics at other companies

Tactile Systems Technology logo
TCMDProduct — Gross Profit
$51.71M+34.0%
Varex Imaging Corporation logo
VREXMedical — Gross Profit
$50.6M-9.5%
Utah Medical Products logo
UTMDGross Profit
$5.28M-4.6%
Biogen logo
BIIBGross Profit
$1.82B+0.8%
Pfizer logo
PFEGross Profit
$10.9B+0.3%
Mesa Laboratories logo
MLABBiopharmaceutical Development — Gross Profit
$5.2M-28.3%

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M—
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity0×—
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GrossProfit.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's remodulin — gross profit.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's remodulin — gross profit?
United Therapeutics (UTHR) reported remodulin — gross profit of $110.5M in Q1 2026.
How has United Therapeutics's remodulin — gross profit changed year-over-year?
United Therapeutics's remodulin — gross profit decreased by 11.2% year-over-year, from $124.4M to $110.5M.
What is the long-term trend for United Therapeutics's remodulin — gross profit?
Over 4 years (2021 to 2025), United Therapeutics's remodulin — gross profit has grown at a 0.1% compound annual growth rate (CAGR), from $475.8M to $477.5M.
What does remodulin — gross profit mean?
Calculated as the total revenue from a specific product line minus the direct cost of sales associated with that product. This metric measures the fundamental profitability of the drug before accounting for research and development, marketing, or administrative expenses. It reflects the core margin potential of the therapeutic asset.